

Telescope Announces Option Grant

Not for Distribution in the United States

Vancouver, BC — November 23, 2021 — Telescope Innovations Corp. ("Telescope" or the "Company") (CSE: TELI) announces that it has granted 1,725,000 incentive stock options (the "Options") to certain directors, officers and consultants of the Company in accordance with the Company's incentive stock option plan. The options vest on March 24, 2022 and are exercisable to acquire common shares of the Company at a price of \$0.90 until November 23, 2026.

About Telescope

Telescope is a chemical technology company developing scalable, widely deployable synthetic processes to access pharmaceuticals for the treatment of mental health. Research and development efforts are focused on medicines from the under-utilized tryptamine class of compounds, leveraging innovative process chemistry to access novel molecules. Our aim is to bring modern chemical solutions to meet the most serious challenges in human health. In pursuit of this goal, we develop and deploy cutting-edge tools to advance the global chemical manufacturing sector.

On behalf of the Board,

Telescope Innovations Corp.

Jason Hein, Chief Executive Officer E: jason@telescopeinn.com

Forward-Looking Information

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.